Business Wire

ANT-INTERNATIONAL

18.6.2024 09:36:33 CEST | Business Wire | Press release

Share
Ant International Unveils Global SME Digital Lending Service Through Embedded Finance to Accelerate Financial Inclusion

Ant International, a leading global digital payment and financial technology provider, today unveiled bettr, a global digital lending service to provide micro lending to micro, small and medium enterprises (MSMEs) in strategic markets through embedded finance partnerships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618515438/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Wallapa Traisorat, CEO and President of Asset World Corporation (second from left) and Yang Peng, CEO of Ant International (second from right) at the MOU signing ceremony between bettr and AWC (Photo: Business Wire)

Yang Peng, CEO of Ant International said, “I’m thrilled to introduce bettr to SMEs and industry partners across emerging markets. This is a major milestone in our journey to empower SMEs worldwide with innovative fintech solutions through open collaboration with regional partners. bettr’s mission is to make financing simpler and more accessible for micro and small businesses as they become the new engine for regional and cross-border trade and commerce. We look forward to expanding partnerships with leaders across industries to achieve our shared vision for an inclusive, sustainable future commerce ecosystem.”

The IFC estimates that 65 million firms, or 40%1 of formal MSMEs in developing countries, have an unmet financing need of $5.2 trillion every year. Recognising the unmet need for inclusive and accessible financial services globally, bettr aims to enable an open, collaborative ecosystem to enhance the accessibility and ease of credit support by leveraging AI, privacy-preserving computing and other digital innovations to close the financing divide and unlock growth opportunities for MSMEs.

Marking the launch, bettr announced its inaugural embedded finance collaboration with Asset World Corporation (“AWC”), Thailand’s leading integrated lifestyle real estate group and a member of the TCC Group. Wallapa Traisorat, CEO and President of AWC said, “AWC is very excited to partner with Ant International for the launch of bettr. This collaboration will allow both parties to fully leverage their strengths where bettr will intuitively avail digital lending to AWC’s ecosystem of micro and small businesses via our various platforms and engagement channels. The first phase of this partnership will launch AWC’s flagship project “Phenix,” the world’s food wholesale hub, featuring the largest food lounge in Pratunam, set to open on 26th June 2024. The partnership is expected to benefit sellers, buyers, and AWC suppliers, conducting business on Phenix both online and offline, and will eventually benefit merchants across AWC’s Hospitality, Retail and Wholesale and Commercial businesses.”

“With a booming SME economy, Thailand has been a strategic market for Ant International from day one, where we learned from deep-rooted partnerships and serve thousands of local businesses through digital payments, connecting them with global travelers and export markets. With bettr, we are now able to expand the financial services offerings by providing accessible financing, empowering small businesses to grow and thrive," added Yang Peng.

About bettr

bettr is the digital lending business under Ant International, focused on providing inclusive financial services to micro, small and medium enterprises (MSMEs) in strategic markets through partners via embedded finance. By leveraging its innovation-led tech like AI and privacy-preserving computing to enable secure financing solutions, bettr enhances the accessibility and ease of financing, unlocking growth opportunities for MSMEs. For more information on bettr, please visit https://www.bettrfinancing.com/

About Ant International

Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.

1 Source: https://www.worldbank.org/en/topic/smefinance

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240618515438/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye